Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment

被引:50
作者
Agosti, Pasquale [1 ]
Sabba, Carlo [1 ]
Mazzocca, Antonio [1 ]
机构
[1] Univ Bari, Interdisciplinary Dept Med, Sch Med, Piazza G Cesare 11, I-70124 Bari, Italy
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2018年 / 1864卷 / 02期
关键词
Hepatocellular carcinoma (HCC); Non-alcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Liver microenvironment; Inflammation; Insulin resistance; ALPHA GENE-EXPRESSION; FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; GUT MICROBIOTA; INTESTINAL MICROBIOTA; URSODEOXYCHOLIC ACID; MEDITERRANEAN DIET; INSULIN-RESISTANCE; DIABETES-MELLITUS; HEPATIC STEATOSIS;
D O I
10.1016/j.bbadis.2017.11.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite the reducing incidence of chronic hepatitis infections, an unexpected increasing incidence of hepatocellular carcinoma (HCC) has being occurred. This may be explained by the increasing number of HCCs developing on steatosis (NAFLD) and steatohepatitis (NASH), related to metabolic risk factors (i.e. diabetes mellitus type II, obesity, metabolic syndrome), which are becoming emerging risk factors for HCC. This led to a growing scientific interest on the oncogenic mechanisms underlying the transition from NAFLD to HCC. However, patients with NASH receive significantly less HCC surveillance than patients with chronic hepatitis, and no specific preventive pharmacological treatments have recommended for NASH-related HCC. This review focuses on the pathogenic role of the emerging factors involved in the transition from NAFLD/NASH to HCC, including microbiota, insulin resistance, inflammation, lipid and bile acids metabolism. It will be emphasize their impact on the liver microenvironment, the implications in clinical practice and the future directions of research.
引用
收藏
页码:607 / 617
页数:11
相关论文
共 100 条
  • [1] Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation
    Afrin, Rejina
    Arumugam, Somasundaram
    Rahman, Azizur
    Wahed, Mir Imam Ibne
    Karuppagounder, Vengadeshprabhu
    Harima, Meilei
    Suzuki, Hiroshi
    Miyashita, Shizuka
    Suzuki, Kenji
    Yoneyama, Hiroyuki
    Ueno, Kazuyuki
    Watanabe, Kenichi
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 44 : 174 - 182
  • [2] Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease
    Aravinthan, Aloysious
    Scarpini, Cinzia
    Tachtatzis, Phaedra
    Verma, Suman
    Penrhyn-Lowe, Sue
    Harvey, Rebecca
    Davies, Susan E.
    Allison, Michael
    Coleman, Nick
    Alexander, Graeme
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 (03) : 549 - 556
  • [3] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [4] Gut microbiota and non-alcoholic fatty liver disease: new insights
    Aron-Wisnewsky, J.
    Gaborit, B.
    Dutour, A.
    Clement, K.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 338 - 348
  • [5] Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan
    Assis-Junior, Eudmar Marcolino
    Melo, Anielle Torres
    Magalhaes Pereira, Venucia Bruna
    Tenazoa Wong, Deysi Viviana
    Pinho Sousa, Nathalia Ribeiro
    Goncalves Oliveira, Christiane Mendes
    Cavalcante Malveira, Lara Raissa
    Moreira, Leonardo Silva
    Loiola Ponte Souza, Marcellus Henrique
    Carvalho Almeida, Paulo Roberto
    Pereira Lima-Junior, Roberto Cesar
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 327 : 71 - 79
  • [6] Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention
    Baffy, Gyorgy
    [J]. JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2013, 1 (02) : 131 - 137
  • [7] Alcohol and HCV Chronic Infection Are Risk Cofactors of Type 2 Diabetes Mellitus for Hepatocellular Carcinoma in Italy
    Balbi, Massimiliano
    Donadon, Valter
    Ghersetti, Michela
    Grazioli, Silvia
    Della Valentina, Giovanni
    Gardenal, Rita
    Dal Mas, Maria
    Casarin, Pietro
    Zanette, Giorgio
    Miranda, Cesare
    Cimarosti, Paolo
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2010, 7 (04) : 1366 - 1378
  • [8] The metabolomic window into hepatobiliary disease
    Beyoglu, Diren
    Idle, Jeffrey R.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 842 - 858
  • [9] Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults
    Borena, Wegene
    Strohmaier, Susanne
    Lukanova, Annekatrin
    Bjorge, Tone
    Lindkvist, Bjorn
    Hallmans, Goran
    Edlinger, Michael
    Stocks, Tanja
    Nagel, Gabriele
    Manjer, Jonas
    Engeland, Anders
    Selmer, Randi
    Haggstrom, Christel
    Tretli, Steinar
    Concin, Hans
    Jonsson, Hakan
    Stattin, Par
    Ulmer, Hanno
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (01) : 193 - 200
  • [10] Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma
    Bugianesi, E
    Leone, N
    Vanni, E
    Marchesini, G
    Brunello, F
    Carucci, P
    Musso, A
    De Paolis, P
    Capussotti, L
    Salizzoni, M
    Rizzetto, M
    [J]. GASTROENTEROLOGY, 2002, 123 (01) : 134 - 140